Company Profile
ARSANIS, INC.
Company Overview
Arsanis is a clinical-stage biotechnology company leading the development of targeted monoclonal antibodies (mAbs) for pre-emptive therapy and treatment of serious infectious diseases. The company’s current programs address pathogenic processes selectively, rather than aiming to broadly eliminate pathogens, potentially allowing Arsanis to address critical infections without contributing to the problem of antimicrobial resistance. The company is building a broad product pipeline addressing the most important infectious diseases that threaten patients globally. Its lead clinical program, ASN100, is being evaluated in a Phase 2 clinical study for the prevention of Staphylococcus aureus pneumonia in high-risk patients.
Arsanis is a US company headquartered in Waltham, Massachusetts, with European research and preclinical development operations headquartered in Vienna, Austria (Arsanis Biosciences GmbH).